Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Camlin Fine Sciences's Debt-to-EBITDA or its related term are showing as below:
NSE:CAMLINFINE'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 2.64 Med: 4.45 Max: 15.81
Current: 6.43
During the past 13 years, the highest Debt-to-EBITDA Ratio of Camlin Fine Sciences was 15.81. The lowest was 2.64. And the median was 4.45.
NSE:CAMLINFINE's Debt-to-EBITDA is ranked worse than 81.54% of 1235
companies
in the Chemicals industry
Industry Median: 2.16
vs NSE:CAMLINFINE: 6.43
Camlin Fine Sciences (NSE:CAMLINFINE) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Camlin Fine Sciences Debt-to-EBITDA Related Terms
Camlin Fine Sciences Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Camlin Fine Sciences's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:CAMLINFINE vs LIN, SHW, ECL: Debt-to-EBITDA Comparison
For the Specialty Chemicals subindustry, Camlin Fine Sciences's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Camlin Fine Sciences Debt-to-EBITDA vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Camlin Fine Sciences's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Camlin Fine Sciences's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Camlin Fine Sciences (NSE:CAMLINFINE) has a Debt-to-EBITDA of 4.22 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Camlin Fine Sciences. This is near median its historical median of 4.45. Over the past decade, Camlin Fine Sciences' Debt-to-EBITDA has ranged from 2.64 to 15.81. According to the industry distribution chart, Camlin Fine Sciences ranks #1007 out of 1235 companies in the Chemicals industry, placing it in the top 81.5%.
Is Camlin Fine Sciences' Debt-to-EBITDA too high?
Camlin Fine Sciences' current Debt-to-EBITDA of 4.22 is near median its 10-year median of 4.45. Over the past 10 years, this metric has ranged from a low of 2.64 to a high of 15.81. The Chemicals industry median Debt-to-EBITDA is 2.16. Camlin Fine Sciences' value of 4.22 is 95.4% above this industry median. Based on the distribution chart, Camlin Fine Sciences ranks #1007 out of 1235 companies in the Chemicals industry, which is in the bottom quartile relative to peers. Overall, Camlin Fine Sciences has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Camlin Fine Sciences' Debt-to-EBITDA compare to LIN and SHW?
According to the Chemicals industry distribution chart, Camlin Fine Sciences ranks #1007 out of 1235 companies for Debt-to-EBITDA. This places Camlin Fine Sciences in the lower half of its industry. The industry median Debt-to-EBITDA is 2.16. Camlin Fine Sciences' value of 4.22 is 95.4% above this benchmark. Historically, Camlin Fine Sciences' own Debt-to-EBITDA has ranged from 2.64 to 15.81 over the past decade. While the company's 10-year median is 4.45 vs. the industry median of 2.16, Camlin Fine Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Chemicals company?
The median Debt-to-EBITDA among Chemicals companies is 2.16, based on 1,235 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Camlin Fine Sciences's current Debt-to-EBITDA of 4.22 is 95.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Camlin Fine Sciences. For the Chemicals industry, the median Debt-to-EBITDA is 2.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Camlin Fine Sciences's current Debt-to-EBITDA is 4.22, which is near median its own 10-year median of 4.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Camlin Fine Sciences stock overvalued right now?
Based on GuruFocus' analysis, Camlin Fine Sciences (NSE:CAMLINFINE) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹143.79, compared to a current price of ₹122.69 — trading 14.7% below its estimated fair value. The current Debt-to-EBITDA is 4.22, which is near median its 10-year median of 4.45 and 95.4% above the Chemicals industry median of 2.16. Camlin Fine Sciences' overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Camlin Fine Sciences (NSE:CAMLINFINE), the current Debt-to-EBITDA is 4.22 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Camlin Fine Sciences (NSE:CAMLINFINE) Overvalued in 2026?
Based on GuruFocus' analysis, Camlin Fine Sciences stock appears to be undervalued.
The current stock price of ₹122.69 is trading 14.7% below its estimated GF Value™ of ₹143.79.
GuruFocus considers Camlin Fine Sciences to be Modestly Undervalued.
Key valuation signals for NSE:CAMLINFINE:
Debt-to-EBITDA: 4.22 (near median its 10-year median of 4.45)
GF Value™: ₹143.79 vs. price of ₹122.69 (14.7% below fair value)
Industry Position: 95.4% above the Chemicals median (#1007 of 1235)
No single metric tells the full story. See the NSE:CAMLINFINE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Camlin Fine Sciences Ltd is engaged in research, development, manufacturing, commercializing, and marketing of specialty chemicals and blends. These chemicals are used in food, feed, animal and pet nutrition and industrial products. The Company has only one reportable segment, namely, Speciality Chemicals. The company's product portfolio consists of Shelf life solutions, Aroma ingredients, Performance chemicals and Health & Wellness. Shelf life extension solutions include antioxidant solutions which are used to increase the shelf life of oils and. Aroma vertical includes a production of Vanillin and Ethyl Vanillin. Performance Chemicals consist of Guaiacol, Veratrole, TBC, and MEHQ and are used in sectors such as food flavoring, pharmaceuticals intermediate fragrance industry.
62GF Score
Get the complete analysis for NSE:CAMLINFINE
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:CAMLINFINE has been successfully added to your 
